Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis

Background Ulcerative colitis (UC) is a chronic and remitting inflammatory disease that is characterized by chronic idiopathic inflammation of the colon and bloody diarrhea. Currently drug treatment is the main intervention for patients with mild to moderate UC. Mesalazine (5-ASA) and beclomethasone dipropionate (BDP) have been widely used for the treatment of UC and have yielded satisfactory results. This study compared the effectiveness of 5-ASA and BDP in the treatment of UC. Methods The PubMed, Medline, SinoMed, Embase, and Cochrane Librinary databases were searched for eligible studies. Data were extracted by two of the coauthors independently and were analyzed using RevMan statistical software, version 5.3. Weighted mean differences (WMDs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated. Cochrane Collaboration’s Risk of Bias Tool was used to assess the risk of bias. Results Seven randomized controlled trials that compared BDP with 5-ASA in treating UC were identified as eligible. The methodological quality of the trials ranged from low to moderate. A pooled analysis of effectiveness based on the Disease Activity Index (DAI) or other assessment method after treatment revealed that in the treatment of UC, there are no obvious differences between BDP and 5-ASA in inducing remission and clinical improvement (OR = 0.76, 95% CI = 0.56–1.03, P = 0.08). The total numbers of adverse events associated with BDP and 5-ASA treatments for UC were similar (OR = 1.21, 95% CI = 0.71–2.09, P = 0.48). The safety profiles for these two drugs are good. According to subgroup-analysis, we found no obvious differences of clinical efficacy between BDP and 5-ASA no matter oral or enema administration was used in the treatment of UC. A sensitivity analysis demonstrated the stability of the pooled results. Conclusion During induction treatment of mild to moderate UC, there is no obvious difference between the two groups with respect to remission and clinical improvement. Given that the upper confidence limit for the OR barely exceeds 1.0 and that the p-value is close to 0.05 for this primary efficacy outcome as well as that the horizontal block lies to the left of the vertical line, it indicates that the clinical efficacy of BDP may be better than 5-ASA. However, taking into account that BDP has the risk of hypothalamic-pituitary-adrenal axis (HPA) suppression, 5-ASA has a potential advantage of safety in the treatment of mild to moderate UC.

[1]  B. Feagan,et al.  Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.

[2]  R. Pica,et al.  Efficacy of mesalazine or beclomethasone dipropionate enema or their combination in patients with distal active ulcerative colitis. , 2015, European review for medical and pharmacological sciences.

[3]  S. Dalal,et al.  Systematic Review: Rectal Therapies for the Treatment of Distal Forms of Ulcerative Colitis , 2015, Inflammatory bowel diseases.

[4]  A. Ananthakrishnan.  Environmental Risk Factors for Inflammatory Bowel Diseases: A Review , 2015, Digestive Diseases and Sciences.

[5]  B. Feagan,et al.  Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta‐analysis , 2012, Inflammatory bowel diseases.

[6]  Michael D. Kappelman,et al.  Recent Trends in the Prevalence of Crohn’s Disease and Ulcerative Colitis in a Commercially Insured US Population , 2012, Digestive Diseases and Sciences.

[7]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.

[8]  C. Papi,et al.  Oral Beclomethasone Dipropionate as an Alternative to Systemic Steroids in Mild to Moderate Ulcerative Colitis Not Responding to Aminosalicylates , 2010, Digestive Diseases and Sciences.

[9]  R. Pica,et al.  P051 Oral Beclomethasone Dipropionate versus 5-Aminosalycilic Acid Enema in Active Ulcerative Colitis Patients: Lower Efficacy but Better Compliance , 2008 .

[10]  F. Manguso,et al.  Meta‐analysis: the efficacy of rectal beclomethasone dipropionate vs. 5‐aminosalicylic acid in mild to moderate distal ulcerative colitis , 2007, Alimentary pharmacology & therapeutics.

[11]  F. Cominelli,et al.  Immunopathogenesis of inflammatory bowel disease: current concepts , 2007, Current opinion in gastroenterology.

[12]  W. Sandborn,et al.  Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.

[13]  V. Annese,et al.  Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[14]  J. Auwerx,et al.  Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ , 2005, The Journal of experimental medicine.

[15]  F. Manguso,et al.  Topical Treatment of Distal Active Ulcerative Colitis With Beclomethasone Dipropionate or Mesalamine: A Single-blind Randomized Controlled Trial , 2005, Journal of clinical gastroenterology.

[16]  I. Adcock,et al.  Effects of glucocorticoids on gene transcription. , 2004, European journal of pharmacology.

[17]  M. Vatn,et al.  Health‐related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis , 2004, Scandinavian journal of gastroenterology.

[18]  A. Kornbluth,et al.  Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee , 2004, American Journal of Gastroenterology.

[19]  P. Gionchetti,et al.  Standard Treatment of Ulcerative Colitis , 2003, Digestive Diseases.

[20]  F. Manguso,et al.  Oral beclometasone dipropionate in the treatment of extensive and left‐sided active ulcerative colitis: a multicentre randomised study , 2003, Alimentary pharmacology & therapeutics.

[21]  F. Manguso,et al.  Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double‐blind placebo‐controlled study , 2002, Alimentary pharmacology & therapeutics.

[22]  P. Rutgeerts,et al.  The limitations of corticosteroid therapy in Crohn’s disease , 2001, Alimentary pharmacology & therapeutics.

[23]  M. Biraghi,et al.  [Topical treatment of ulcerative colitis. Doubleblind study between beclomethasone dipropionate and mesalazine]. , 1999, Minerva Gastroenterologica e Dietologica.

[24]  N. Stollman,et al.  Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. , 1999, The American journal of gastroenterology.

[25]  P. Fockens,et al.  Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. , 1996, European journal of gastroenterology & hepatology.

[26]  L. Sutherland,et al.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. , 1987, Gastroenterology.

[27]  Jürg Müller,et al.  Treatment of distal ulcerative colitis with beclomethasone enemas: High therapeutic efficacy without endocrine side effects , 1987, Diseases of the colon and rectum.

[28]  C. Kumana,et al.  BECLOMETHASONE DIPROPIONATE ENEMAS FOR TREATING INFLAMMATORY BOWEL DISEASE WITHOUT PRODUCING CUSHING'S SYNDROME OR HYPOTHALAMIC PITUITARY ADRENAL SUPRESSION , 1982, The Lancet.

[29]  P. Forgacs,et al.  Treatment of intestinal gas cysts by oxygen breathing. , 1973, Lancet.

[30]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.

[31]  C. FordAlexander,et al.  ULCERATIVE colitis. , 1997, Journal of the American Medical Association.

[32]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .

[33]  S. Truelove.  Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. , 1954, Gastroenterologia.

[34]  Slocumb Ch,et al.  The effects of the adrenal cortical hormone 17-hydroxy-11-dehydrocorticosterone (Compound E) on the acute phase of rheumatic fever; preliminary report. , 1949 .

[35]  C. Slocumb,et al.  The effects of the adrenal cortical hormone 17-hydroxy-11-dehydrocorticosterone (Compound E) on the acute phase of rheumatic fever; preliminary report. , 1949, Proceedings of the staff meetings. Mayo Clinic.